Compare Citius Pharmaceuticals Inc (CTXR) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Visa Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Visa Inc trades at $362.79 (market cap $668.96B). The key difference: Visa Inc is far larger — about 35716× Citius Pharmaceuticals Inc's market cap, and Visa Inc pays a 0.74% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | V | |
|---|---|---|
Market Cap | $18.73M | $668.96B |
Sector | Health | Financials |
52-Week High | $1.82 | $370.47 |
52-Week Low | $0.48 | $295.52 |
Enterprise Value | $14.95M | $679.54B |
Volume | — | 10,431,336 |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Visa (V) trades at $361.32, down 0.33% on the day, with strong fundamentals including 50.78% net income margin and consistent earnings beats. The stock shows bearish technical signals but maintains bullish moving averages. Recent developments include AI-powered commerce initiatives and stablecoin partnerships, positioning Visa for future payment system evolution. Financial trends show revenue growth from $29.3B in 2022 to $40B in 2025, with robust cash flow generation.
Visa presents a compelling long-term investment with 85% analyst buy ratings and $426.31 consensus price target suggesting 18% upside. Key risks include fintech competition and regulatory pressures, but the company's dominant market position, high profitability, and innovation in digital payments support continued growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
